Subcutaneous Drug Delivery Market
                     Subcutaneous Drug Delivery Market- Size, Share, Outlook, and Opportunity 
Analysis, 2020- 2027
Subcutaneous drug delivery has emerged as a promising and viable alternative 
to intravenous administration. The rising demand for subcutaneous drug delivery 
is attributed to the rapid development of biologics. Moreover, the subcutaneous 
route of administration is generally preferred, as it enables self-medication, 
improves quality of life, and thus reduces healthcare costs.
Request a sample copy of this report:- 
https://www.coherentmarketinsights.com/insight/request-sample/2933 
Furthermore, convenience and safety for both patients and medical professionals
offered  by  subcutaneous  devices  are  major  factors  leading  to  growth  of  the
global  subcutaneous  drug  delivery  market.  According  to  the  World  Health
Organization,  2014,  around  2  million  healthcare  professionals  suffered  from
infectious  diseases  as  result  of  needlestick  injuries,  globally.  The  retractable
nature of prefilled syringes help to overcome this problem, thereby acting as an
ideal device to reduce the occurrence of needlestick injuries.
Increasing focus of  manufacturers  on adoption of  inorganic  growth strategies
such  as  collaboration  and  partnership,  in  order  to  strengthen  their  product
portfolio of subcutaneous drug delivery systems is expected to drive the market
growth over the forecast  period.  For instance, in October 2017, EVER Neuro
Pharma GmbH acquired PHARMAGEN CZ s.r.o, a company that specializes in
injectable segment, located in Slovakia, Europe.
Preference  for  safety  injection  devices  is  increasing  among  healthcare
professionals  and  manufacturers,  as  these  devices  decrease  the  chances  of
needlestick injuries. For instance, WHO recommended the use of safety syringes
with  sharp  injury  protection  (SIP)  in  order  to  prevent  needlestick  injuries.
Moreover,  in  May  2017,  Innovative  Neurons  LLC  announced  its  plan  to
commercialize its patented auto retractable multi-needle syringe known as FAST
(fast, accessible, safe, and technology), to decrease needlestick injuries. In 2016,
Nipro Medical Corporation launched 'SafeTouch' safety needle,  which protects
patients from needlestick injuries.
The unavailability  of  approved products  due to  increasing number  of  product
recalls  by  various  developers  is  a  factor  hindering  growth  of  the  global
subcutaneous drug delivery market. For instance, on May 18, 2020, Bausch &
Lomb UK Limited announced a recall of Emerade 500 microgram auto-injectors,
owing to error in one component of auto injector,  which caused the failure to
activate the pen and deliver adrenaline drug. Moreover, in April  2018, Becton
Dickson  and  Company  announced  recall  of  PosiFlush  Heaparin  Lock  Flush
Syringe and Prefilled normal saline syringe, owing to contamination with Serratia
marcescens bacterium.
COVID-19 can affect the economy in three main ways; by directly affecting the
production and demand; by creating disruptions in distribution channels; and by
its  financial  impact  on  firms  and  financial  markets.  Supply  chain  and
manufacturing activities in India, China, and the U.S. are being disrupted due to
global lockdown while many countries such as Saudi Arabia, UAE, Egypt, and
others are facing problems with regards to transportation of drugs from one place
to another.
The stockpiling of subcutaneous or oral formulations due to the lockdown may
cause a spike in demand for certain products. According to an article published in
the Center for Biosimilars (American Journal of Managed Care), on February 27,
2020, manufacturers such as Novartis AG who have manufacturing facilities in
Austria, Europe, are particularly at risk on the supply side.
Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit
growth  of  the  global  subcutaneous  drug  delivery  market  during  the  forecast
period.
Major players operating in the global subcutaneous drug delivery market include
Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi
S.A.,  Novartis  International  AG,  Amgen,  Inc.,  Teva  Pharmaceutical  Industries
Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and
Merck  &  Co.,  Inc.,  Novartis  International  AG,  Insulet  Corporation,  West
Pharmaceutical Services, Inc., and Gerresheimer AG.
Get the main link:-  https://www.coherentmarketinsights.com/market-insight/subcutaneous-
drug-delivery-market-2933 
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/